Pharmaceutical care of one case of hypoparathyroid cardiomyopathy

doi:10.19803/j.1672-8629.20210412

Abstract

Abstract: Objective To explore the treatment plan for one patient with hypoparathyroid cardiomyopathy, and to provide reference for clinical rational use of drugs. Methods The rationality of the medication was evaluated by combining the related literature with the pharmaceutical care of this patient. Results The increase of blood calcium levels was critical to the treatment of hypoparathyroid cardiomyopathy. Therefore, the dose of calcium supplements had to be increased once hypocalcemia was hard to improve. Hydrochlorothiazide, a thiazide diuretic with calcium-preserving effect, should be the candidate instead of furosemide. Meanwhile, improving hypomagnesemia contributed to the curative effect. Conclusion Pharmacists can help ensure the safety, effectiveness and rationality of drug use by participating in the treatment of patients with hypoparathyroid cardiomyopathy, assisting physicians in formulating and optimizing treatment plans, and implementing full-course pharmaceutical monitoring.

Key words: hypoparathyroid, cardiomyopathy, pharmaceutical care, clinical pharmacist, rational drug use

CLC Number:

R994.11
R977

LI Youjia, XIE Jiao, YAO Hongyi, JI Cheng. Pharmaceutical care of one case of hypoparathyroid cardiomyopathy[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1254-1257.

References

[1] Chinese Society of Osteoporosis and Bone Mineral Research, Chinese Society of Endocrinology, Metabolic Osteopathy Group. Guidelines for clinical diagnosis and treatment of hypoparathyroidism[J]. Chin J Osteoporosis & Bone Miner Res(中华骨质疏松和骨矿盐疾病杂志), 2018, 11(4): 323-338.
[2] ZHAO C.Hypoparathyroid and cardiac damage[J]. Adv Cardiovasc Dis, 2016, 37(2): 133-136.
[3] JAWAID I, RAJESH S.Hyperparathyroidism (primary) NICE guideline: diagnosis, assessment, and initial management[J]. British Journal of General Practice, 2020, 70: 362-363.
[4] XIAO YG, ZHANG QY, TANG ZH.Pharmaceutical care of a case of hypoparathyroidism after thyroid cancer operation[J]. Herald Med(医药导报), 2017, 36(11): 1271-1273.
[5] ZHANG YR.A systematic review of hypoparathroid cardiomyopathy[J]. Clinical Focus, 2020, 35(9): 783-787.
[6] SAINI N, MISHRA S, BANERJEE S, et al.Hypocalcemic cardiomyopathy: a rare presenting manifestation of hypoparathyroidism[J]. BMJ Case Reports, 2019, 12(9): e229822.
[7] SHOBACK D.Clinical practice. Hypoparathyroidism[J]. N Engl J Med, 2008, 359(4): 391-403.
[8] Chinese Society of Cardiology, Chinese Myocarditis and Cardiomyopathy Collaborative Group. Chinese guidelines for the diagnosis and treatment of dilated cardiomyopathy[J]. Journal of Clinical Cardiology(临床心血管病杂志), 2018, 34(5): 421-434.
[9] CHENG SX, WANG YB, WANG O, et al.Comparison of effectiveness and safety of high-dose native vitamin D versus active vitamin D in the treatment of hypoparathyroidism[J]. Chin J Endocrinol Metab, 2019, 35(10): 859-863.
[10] YOKOKAWA T, SAKAMOTO K, MIZUNO H, et al.A case of massive pericardial effusion associated with hypocalcemic cardiomyopathy[J]. Journal of Cardiology Cases, 2014, 10(2): 58-61.
[11] ALEXANDER RT, DIMKE H.Effect of diuretics on renal tubular transport of calcium and magnesium[J]. Am J Physiol Renal Physiol, 2017, 312(6): 998-1015.
[12] PORTER RH, COX BG, HEANEY D, et al.Treatment of hypoparathyroid patients with chlorthalidone[J]. N Engl J Med, 1978, 298(11): 577-581.
[13] WANG X.Clinical characteristics of hypoparathyroidism: a retrospective analysis of 129 cases[D]. Tianjin: Tianjin Medical University, 2018.
[14] TAO OH, SHEN Z, CAO GW, et al.Eight cases of hypocalcemia induced by tigecycline[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 18(1): 77-79.
[15] SAINI N, MISHRA S, BANERJEE S, et al.Hypocalcemic cardiomyopathy: a rare presenting manifestation of hypoparathyroidism[J]. BMJ Case Rep, 2019, 12(9): e229822.